Medical/Pharmaceuticals

"Transfersome Gel" a New Solution for Hypertrophic Scars Chula Pharmacy's Latest Innovation

BANGKOK, Sept. 16, 2024 /PRNewswire/ -- Lecturers at the Faculty of Pharmaceutical Sciences,Chulalongkorn University , have developed an alternative "Transfersome Gel" to help treat hypertrophic scars and dark marks. This gel, made from a key substance found in the In...

2024-09-16 10:00 1855

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

* In Phase Ia clinical study, GZR4 demonstrated favorable safety and tolerability profiles in healthy subjects, maintaining a stable glucose-lowering effect for up to one week with a single administration. * In Phase Ib clinical study, patients with Type 2 diabetes mellitus (T2DM) receiving s...

2024-09-14 19:00 4010

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

ROCKVILLE, Md. and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-09-14 08:18 3734

Opening Ceremony of BMC France Office

LILLE, France, Sept. 13, 2024 /PRNewswire/ -- On September 12, 2024, BMC held a grand opening ceremony at its new office in Marcq-en-Barœul,France. Employees from acrossEurope and members of the company leadership team attended this event. During the celebration, George Zhuang, President and Gen...

2024-09-13 19:13 978

GSK shingles vaccine now available in Malaysia

A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR, Malaysia, Sept. 13, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine,Shingrix (MAL24056002ARZ), ...

2024-09-13 15:07 2112

BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk

SINGAPORE, Sept. 13, 2024 /PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is proud to join the global community in raising awareness about lymphoma on World Lymphoma Awareness Day (WLAD). Lymphoma, a type of blood cancer affecting millions of peo...

2024-09-13 09:00 2072

Aurora Biosynthetics Launches to Revolutionize RNA Therapeutics Manufacturing

SYDNEY, Sept. 13, 2024 /PRNewswire/ -- Aurora Biosynthetics, a pioneering advanced RNA therapeutics manufacturing company, announced its official launch. This heralds a new era in RNA therapeutics manufacturing across theAsia-Pacific region. Aurora Biosynthetics is poised to meet the surging dema...

2024-09-13 04:00 2310

ZEISS Redefines Disease Management and Treatment within the ZEISS Retina Workflow

Showcasing at EURETINA 2024: ZEISS will highlight new surgical innovations and artificial intelligence (AI) tools for retinal patient care, helping doctors diagnose and treat patients efficiently and effectively:  * THE FUTURE OF VITREORETINAL SURGERY: Demonstrating the ZEISS ARTEVO 850 3D dig...

2024-09-12 20:00 1704

Genea Biomedx solidifies its exclusive partnership in Australia with Genea Fertility

SYDNEY, Sept. 12, 2024 /PRNewswire/ -- Genea Biomedx, which was once part of Genea Fertility, joined the Basecare Medical group in 2023 with the aim of distributing Basecare's assisted reproductive technology internationally. ...

2024-09-12 17:44 1500

SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024

The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announc...

2024-09-12 16:00 1271

Berlin Heals Strengthens Executive Leadership Team

Berlin Heals appoints proven cardiac rhythm management and heart failure leader John Brumfield as Chief Executive Office BERLIN, Sept. 12, 2024 /PRNewswire/ -- Berlin Heals Holding AG and its subsidiaries Berlin Heals GmbH and Berlin Heals Corp. which are developing a completely new and groundbr...

2024-09-12 16:00 1637

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI

SINGAPORE, Sept. 12, 2024 /PRNewswire/ -- Qritive, a leading digital pathology and AI company headquartered inSingapore, is proud to announce its collaboration with Roche, one of the largest diagnostics and life sciences companies in the world. This collaboration represents a significant mileston...

2024-09-12 14:35 1865

BMC at ERS 2024: Exploring the Future of Sleep and Respiratory Health

BEIJING, Sept. 12, 2024 /PRNewswire/ -- From September 7th to September 11th, the European Respiratory Society (ERS) Congress successfully concluded in Vienna, Austria. The ERS Congress is an annual event that brings together the world's respiratory experts to showcase the latest advances in respi...

2024-09-12 13:47 950

NCCN Commits to Sharing Award-Winning Resources for People with Cancer in Spanish and Other Languages

Translations are underway for the entire library of NCCN Guidelines for Patients to empower people with cancer and caregivers worldwide to make informed treatment decisions that are best for them. PLYMOUTH MEETING, Pa., Sept. 12, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (N...

2024-09-12 09:02 1318

Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024

SAN FRANCISCO and SUZHOU, China, Sept. 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic,...

2024-09-12 08:00 2250

Tinnitus Quest Launches to Find a Cure for Hearing Disorder Affecting Millions

WIESBADEN, Germany, Sept. 11, 2024 /PRNewswire/ -- Up to one in every fifty people suffers from a debilitating form of tinnitus, a chronic ringing or buzzing in the ears. It often ruins daily lives, affecting sleep, concentration, and relationships, making it a major cause of mental health probl...

2024-09-11 21:30 2730

FLOWPHYSIX ANNOUNCES STRATEGIC PARTNERSHIP WITH 3COMMA FOR INTERNATIONAL DISTRIBUTION OF INNOVATIVE THROMBECTOMY DEVICE

PLEASANTON, Calif., Sept. 11, 2024 /PRNewswire/ -- FlowPhysix™ Inc, formerly known as Expanse ICE, is pleased to announce a strategic partnership with 3comma Medical / 3comma Medical GmbH who will serve as the international commercial partner for the FLOWRUNNER™ Aspiration System. 3comma is an i...

2024-09-11 21:01 1300

Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC

SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...

2024-09-11 08:00 1800

Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD

SHANGHAI, Sept. 11, 2024 /PRNewswire/ -- Nuance Pharma today announced it has completed the recruitment of patients for the ENHANCE-CHINA (NCT05743075) study, after planned number of patients have been successfully enrolled. The ENHANCE-CHINA study is a phase 3, randomized, double-blind, placebo-...

2024-09-11 08:00 1724

'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology

MELBOURNE, Australia, Sept. 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET[2] agent,...

2024-09-11 06:46 1424
1 ... 13141516171819 ... 397